(Q47793228)

English

Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian

scientific article published on 19 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian (English)

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

brain metastasis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Mustafa Oktay Tarhan

22

object named as

Mustafa Oktay Tarhan

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

25

object named as

Zuhat Urakci

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

author name string

Muhammet Ali Kaplan

1

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Abdurrahman Isikdogan

2

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Doğan Koca

3

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Mehmet Kucukoner

4

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Ozge Gumusay

5

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Ramazan Yildiz

6

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Adem Dayan

7

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Lütfiye Demir

8

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Caglayan Geredeli

9

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Murat Kocer

10

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Ulku Yalcintas Arslan

11

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Ali Inal

12

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Tulay Akman

13

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Ugur Coskun

14

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Nur Sener

15

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Mevlude Inanc

16

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Emin Tamer Elkiran

17

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Nuriye Yildirim Ozdemir

18

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Ayse Gok Durnalı

19

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Ali Suner

20

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Suleyman Alici

21

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Cem Boruban

23

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Berna Oksuzoglu

24

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

publication date

19 January 2013

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

21

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

6

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

677-683

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

https://scigraph.springernature.com/pub.10.1007/s12282-013-0441-y

0 references

CNS metastases in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Breast cancer brain metastases

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Breast cancer metastasis to the central nervous system

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Brain metastases: current management and new developments

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT).

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Breast cancer subtypes and outcomes of central nervous system metastases.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Long-term survival with metastatic cancer to the brain

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0441-Y

21 January 2018

Identifiers

10.1007/S12282-013-0441-Y

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/23335064

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47793228&oldid=1879704807"